High tumor cell expression of microRNA-21 in node positive non-small cell lung cancer predicts a favorable clinical outcome

BMC Clinical Pathology

Roy M Bremnes¹  Lill-Tove Busund²  Mona Irene Pedersen²  Andrej Valkov²  Samer Al-Saad²  Sigve Andersen¹  Tom Donnem¹  Helge Stenvold¹ 

[1] Department of Oncology, University Hospital of North Norway, Tromso 9038, Norway;Dept of Clinical Pathology, University Hospital of North Norway, Tromso, Norway

关键词: miRNA;    miR-21;    Prognostic impact;    Survival;    Stage I-IIIA;    NSCLC;   

Others  :  821509
DOI  :  10.1186/1472-6890-14-9

 received in 2013-05-16, accepted in 2014-01-27,  发布年份 2014

【 摘 要 】

Background

MicroRNA (miR)-21 has been revealed as an oncogene in cancer development, and is one of the miRNAs closely connected to angiogenesis. We aimed to explore the impact of miR-21 expression in both tumor and stromal compartments of non-small cell lung cancer (NSCLC), and correlations between miR-21 and angiogenic protein markers.

Methods

From 335 unselected stage I to IIIA NSCLC carcinomas, duplicate tumor and tumor-associated stromal cores were collected in tissue microarrays (TMAs). In situ hybridization (ISH) was used to detect the expression of miR-21 separately in tumor cells and stromal cells of the tumor, and immunohistochemistry (IHC) was used to detect the expression of the protein markers protein kinase B (Akt), phosphatidylinositol-3-kinase (PI3K), hypoxia induced factor 1 (HIF1α) and vascular endothelial growth factor-A (VEGF-A).

Results

In univariate analyses, high tumor cell expression of miR-21 in patients with lymph node metastasis was a positive prognostic factor (P = 0.024). High stromal miR-21 expression had a negative prognostic impact (P = 0.022). In the multivariate analysis, low tumor mir-21 expression in node positive patients was an independent adverse prognostic factor (HR 2.03, CI 95% 1.09-3.78, P = 0.027).

Conclusions

In patients with lymph node metastasis, miR-21 expression in tumor cells is an independent positive prognostic factor. High stromal miR-21 expression is a negative prognostic factor.

【 授权许可】

   
2014 Stenvold et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
• [2]Fu X, Han Y, Wu Y, Zhu X, Lu X, Mao F, et al.: Prognostic role of microRNA-21 in various carcinomas: a systematic review and Meta-analysis. Eur J Clin Invest 2011, 41:1245-53.
• [3]Iorio MV, Croce CM: MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009, 27:5848-5856.
• [4]Kasinski AL, Slack FJ: Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011, 11:849-864.
• [5]Krichevsky AM, Gabriely G: miR-21: a small multi-faceted RNA. J Cell Mol Med 2009, 13:39-53.
• [6]Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y, et al.: MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev 2009, 23:2152-2165.
• [7]Suarez Y, Sessa WC: MicroRNAs as novel regulators of angiogenesis. Circ Res 2009, 104:442-454.
• [8]Donnem T, Fenton CG, Lonvik K, Berg T, Eklo K, Andersen S, et al.: MicroRNA Signatures in Tumor Tissue Related to Angiogenesis in Non-Small Cell Lung Cancer. PLoS One 2012, 7:e29671.
• [9]Liu LZ, Li C, Chen Q, Jing Y, Carpenter R, Jiang Y, et al.: MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression. PLoS One 2011, 6:e19139.
• [10]Sabatel C, Malvaux L, Bovy N, Deroanne C, Lambert V, Gonzalez ML, et al.: MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. PLoS One 2011, 6:e16979.
• [11]Gao W, Yu Y, Cao H, Shen H, Li X, Pan S, et al.: Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother 2010, 64:399-408.
• [12]Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, et al.: MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 2010, 16:430-441.
• [13]Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES: Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 2008, 54:1696-1704.
• [14]Saito M, Schetter AJ, Mollerup S, Kohno T, Skaug V, Bowman ED, et al.: The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res 2011, 17:1875-1882.
• [15]Voortman J, Goto A, Mendiboure J, Sohn JJ, Schetter AJ, Saito M, et al.: MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 2010, 70:8288-8298.
• [16]Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M: MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg 2008, 12:2171-2176.
• [17]Nielsen BS, Jorgensen S, Fog JU, Sokilde R, Christensen IJ, Hansen U, et al.: High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis 2011, 28:27-38.
• [18]Andersen S, Eilertsen M, Donnem T, Al-Shibli K, Al-Saad S, Busund LT, et al.: Diverging prognostic impacts of hypoxic markers according to NSCLC histology. Lung Cancer 2011, 72:294-302.
• [19]Al-Saad S, Donnem T, Al-Shibli K, Persson M, Bremnes RM, Busund LT: Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer. Anticancer Res 2009, 29:4175-4183.
• [20]Donnem T, Al-Saad S, Al-Shibli K, Delghandi MP, Persson M, Nilsen MN, et al.: Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res 2007, 13:6649-6657.
• [21]Rami-Porta R, Chansky K, Goldstraw P: Updated lung cancer staging system. Future Oncol 2009, 5:1545-1553.
• [22]Jorgensen S, Baker A, Moller S, Nielsen BS: Robust one-day in situ hybridization protocol for detection of microRNAs in paraffin samples using LNA probes. Methods 2010, 52:375-381.
• [23]Yang M, Shen H, Qiu C, Ni Y, Wang L, Dong W, et al.: High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer 2012, 49:604-15.
• [24]Gregg JL, Brown KE, Mintz EM, Piontkivska H, Fraizer GC: Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection. BMC Cancer 2010, 10:165. BioMed Central Full Text
• [25]Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.